Core Viewpoint - The company plans to utilize temporarily idle raised funds for cash management, ensuring safety and liquidity while aiming to enhance returns for the company and its shareholders [2][3][20]. Investment Overview - **Investment Purpose**: The objective is to improve the efficiency of raised funds, ensuring that the use of these funds does not affect project construction and safety, while increasing returns for the company and shareholders [3]. - **Investment Amount**: The company intends to use up to RMB 300 million (including principal) for cash management, with a validity period of 12 months from the board's approval [4][16]. - **Source of Funds**: The cash management funds will come from temporarily idle raised funds from the company's initial public offering in 2019 [5]. Fund Management - **Fund Usage**: The raised funds from the IPO amounted to RMB 1,588.29 million, with a net amount of RMB 1,529.27 million after deducting issuance costs. All funds have been deposited in a special account approved by the board [6][24]. - **Investment Projects**: The raised funds are allocated for international pharmaceutical R&D and working capital, with adjustments made to project timelines as necessary [7][23]. Investment Methodology - **Investment Products**: The company will invest in low-risk, liquid, and capital-protected products such as agreement deposits, notice deposits, time deposits, large certificates of deposit, and income certificates, with a maximum term of 12 months [10][16]. - **Implementation**: The board authorizes the management to make investment decisions within the approved limits and timeframe, with the finance department responsible for execution [11]. Cash Management Returns - **Return Allocation**: Earnings from cash management will be prioritized to cover any shortfalls in project investment amounts and will be managed according to regulatory requirements [12]. Recent Cash Management Situation - **Recent 12-Month Overview**: The authorization for cash management is valid for 12 months, allowing for rolling use of funds within the specified limits [13][14]. Board Approval Process - **Approval Details**: The board approved the cash management proposal on November 7, 2025, confirming that it would not affect the normal operation of the company's investment plans [15][21]. Impact on Company - **Operational Impact**: The planned cash management will not affect the normal operations or project funding of the company, and it aims to generate additional investment returns [20][29].

Core Viewpoint - The company plans to utilize temporarily idle raised funds for cash management to enhance fund efficiency and generate additional returns for the company and its shareholders [3][9][18]. Investment Overview - **Investment Purpose**: The aim is to improve the efficiency of raised fund usage while ensuring that it does not affect the construction and use of the raised fund projects [3]. - **Investment Amount**: The company intends to use up to RMB 300 million (including principal) for cash management, with a validity period of 12 months from the board's approval [4][14]. - **Source of Funds**: The funds for this cash management initiative come from the temporarily idle raised funds from the company's initial public offering in 2019 [5]. Investment Details - **Investment Products**: The company will invest in low-risk, liquid, and capital-protected financial products, including but not limited to agreement deposits, notice deposits, time deposits, large certificates of deposit, and income certificates [2][10]. - **Implementation Method**: The board authorizes the management to make investment decisions within the approved limits and timeframe, with the finance department responsible for execution [11][14]. Recent Cash Management Situation - The company has previously authorized cash management of up to RMB 400 million, with the latest authorization allowing for up to RMB 300 million [13][26]. Impact on the Company - The planned cash management will not affect the normal operation of the company's main business or the normal turnover of funds, and it aims to generate investment returns for the company and its shareholders [18][20]. Sponsor's Verification Opinion - The sponsor, UBS Securities, has confirmed that the cash management initiative has been approved by the board and complies with relevant laws and regulations, ensuring that it does not alter the intended use of raised funds [19][20].

Core Viewpoint - Haohai Biological Technology (06826.HK) announced the acquisition of the remaining 20% equity in Shenzhen New Industry Ophthalmic New Technology Co., Ltd. for RMB 74 million, aiming to enhance its market competitiveness in the ophthalmic high-value consumables sector [1]. Group 1: Acquisition Details - The acquisition agreement was signed between Shanghai Haohai Pharmaceutical Technology Development Co., Ltd. (a wholly-owned subsidiary of the company) and the sellers, which include Zhang Jinsong, Shenzhen Jiusi, and Shenzhen Bainai [1]. - Upon completion of the acquisition, the company will hold 100% equity in the target company, which specializes in the manufacturing and sales of orthokeratology lenses and intraocular lenses, as well as the distribution of various imported ophthalmic products in mainland China [1]. Group 2: Strategic Importance - The company has progressively entered the ophthalmic high-value consumables market since acquiring 60% and 20% stakes in the target company in November 2016 and February 2023, respectively [1]. - The target company has become a key subsidiary, contributing to the company's position as a leading manufacturer of intraocular lenses in China [1]. - The acquisition is expected to improve management and operational efficiency of the target company, thereby enhancing the overall competitiveness of the company's ophthalmic products [1].

Core Viewpoint - Haohai Biological Technology (06826) announced the acquisition of the remaining 20% equity in Shenzhen New Industry Ophthalmic Technology Co., Ltd. for RMB 74 million, aiming to enhance its market position in the ophthalmic high-value consumables sector [1] Group 1: Acquisition Details - The acquisition agreement was signed on November 7, 2025, between Haohai's wholly-owned subsidiary Shanghai Haohai Pharmaceutical Technology and the sellers [1] - After the completion of this acquisition, the company will hold 100% equity in the target company [1] Group 2: Target Company Overview - The target company specializes in the manufacturing and sales of orthokeratology lenses and artificial lenses, as well as the distribution of various imported ophthalmic products in mainland China [1] - The company has been progressively entering the ophthalmic high-value consumables market since acquiring 60% and 20% stakes in 2016 and 2023, respectively [1] Group 3: Strategic Importance - The acquisition is expected to improve the management and operational efficiency of the target company, thereby enhancing the competitiveness of the company's ophthalmic products in the market [1] - The board believes that this acquisition aligns with the company's development needs and overall business strategy [1]

Core Viewpoint - The company, Haohai Biological Technology, is acquiring the remaining 20% equity of Shenzhen New Industry Ophthalmic New Technology Co., Ltd. for RMB 74 million, aiming to enhance its management and operational efficiency in the ophthalmic high-value consumables sector [1] Group 1: Acquisition Details - The acquisition agreement involves Haohai's wholly-owned subsidiary, Shanghai Haohai Pharmaceutical Technology, as the acquirer and includes the transfer of equity from Mr. Zhang, Shenzhen Jiusi, and Shenzhen Baina [1] - Upon completion of the acquisition, the company will hold 100% equity in the target company, which specializes in the manufacturing and sales of orthokeratology lenses and artificial lenses [1] Group 2: Strategic Importance - The target company has been a significant subsidiary since Haohai acquired 60% and 20% stakes in November 2016 and February 2023, respectively [1] - The acquisition aligns with the company's strategic goal to strengthen its position as a leading manufacturer of artificial lenses in China and improve market competitiveness in ophthalmic products [1]

Core Viewpoint - Haohai Biological Technology (06826.HK) announced the acquisition of the remaining 20% equity in Shenzhen New Industry Ophthalmic New Technology Co., Ltd. for RMB 74 million, aiming to enhance its management and operational efficiency in the ophthalmic high-value consumables sector [1] Group 1: Acquisition Details - The acquisition agreement was signed between Shanghai Haohai Pharmaceutical Technology Development Co., Ltd. (a wholly-owned subsidiary of the company) and the sellers (Zhang Jinsong, Shenzhen Jiusi, and Shenzhen Bainai) [1] - Upon completion of the acquisition, the company will hold 100% equity in the target company [1] Group 2: Target Company Overview - The target company is a limited liability company established in China, primarily engaged in the manufacturing and sales of orthokeratology lenses and intraocular lens products [1] - It also distributes various imported ophthalmic products, including intraocular lenses, ophthalmic viscoelastic devices, and sodium hyaluronate gel for glaucoma surgery in mainland China [1] Group 3: Strategic Importance - The company has progressively entered the ophthalmic high-value consumables market since acquiring 60% and 20% stakes in the target company in November 2016 and February 2023, respectively [1] - The target company has become one of the main subsidiaries of the group, contributing to its position as a leading manufacturer of intraocular lens products in China [1] - The board believes that the acquisition aligns with the company's development needs and overall business planning, enhancing market competitiveness in ophthalmic products [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 關連交易 收購一家非全資子公司的 餘下20%股權 茲提述本公司日期為2023年2月8日的公告及本公司日期為2023年3月9日的補充 公告，內容有關受讓方向前轉讓方收購目標公司20%股權。於2023年完成該項 收購後，本公司間接擁有目標公司80%股權。 (i) 張先生 ：張先生為目標公司的董事，因而屬本公司子公司層面的關連人士。 (ii) 深圳百納 ：張彩霞女士為目標公司的董事，因而屬本公司子公司層面的關 連人士。深圳百納為一家有限合夥企業，張彩霞女士為有限合夥人，擁有 深圳百納46.5%份額，因而深圳百納為張彩霞女士的聯繫人，因而亦為本公 司子公司層面的關連人士。 緒言 茲提述本公司日期為2023年2月8日的公 ...

智通财经APP讯，昊海生物科技(06826)发布公告，于2025年11月7日，该公司斥资146.18万港元回购5.31 万股股份，每股回购价格为27.34-27.6港元。 ...

Core Viewpoint - Haohai Biological Technology (06826) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company will repurchase 53,100 shares at a total cost of HKD 1.4618 million [1] - The buyback price per share ranges from HKD 27.34 to HKD 27.60 [1]

格隆汇11月7日丨昊海生物科技(06826.HK)公告，11月7日耗资146.2万港元回购5.3万股。 ...